Rubedo Life Sciences co-founder Julian Klein (foreground) with CEO Marco Quarta (courtesy Rubedo Life Sciences)
April 22, 2024 08:36 AM EDTUpdated 08:55 AM
Financing

Rube­do pulls in $40M Se­ries A to ad­vance atopic der­mati­tis can­di­date tar­get­ing ag­ing cells

Katherine Lewin

News Reporter

Rube­do Life Sci­ences is fur­ther­ing its plan to treat age-re­lat­ed dis­eases by tar­get­ing senes­cent cells with a $40 mil­lion Se­ries A led by Khosla Ven­tures …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

A service from the Financial Times